These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38135187)

  • 1. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study.
    Chuong MD; Lee P; Low DA; Kim J; Mittauer KE; Bassetti MF; Glide-Hurst CK; Raldow AC; Yang Y; Portelance L; Padgett KR; Zaki B; Zhang R; Kim H; Henke LE; Price AT; Mancias JD; Williams CL; Ng J; Pennell R; Raphael Pfeffer M; Levin D; Mueller AC; Mooney KE; Kelly P; Shah AP; Boldrini L; Placidi L; Fuss M; Jitendra Parikh P
    Radiother Oncol; 2024 Feb; 191():110064. PubMed ID: 38135187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
    Parikh PJ; Lee P; Low DA; Kim J; Mittauer KE; Bassetti MF; Glide-Hurst CK; Raldow AC; Yang Y; Portelance L; Padgett KR; Zaki B; Zhang R; Kim H; Henke LE; Price AT; Mancias JD; Williams CL; Ng J; Pennell R; Pfeffer MR; Levin D; Mueller AC; Mooney KE; Kelly P; Shah AP; Boldrini L; Placidi L; Fuss M; Chuong MD
    Int J Radiat Oncol Biol Phys; 2023 Nov; 117(4):799-808. PubMed ID: 37210048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study.
    Bordeau K; Michalet M; Keskes A; Valdenaire S; Debuire P; Cantaloube M; Cabaillé M; Portales F; Draghici R; Ychou M; Assenat E; Mazard T; Samalin E; Gauthier L; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART).
    Bryant JM; Palm RF; Herrera R; Rubens M; Hoffe SE; Kim DW; Kaiser A; Ucar A; Fleming J; De Zarraga F; Hodul P; Aparo S; Asbun H; Malafa M; Jimenez R; Denbo J; Frakes JM; Chuong MD
    Cancer Control; 2023; 30():10732748221150228. PubMed ID: 36598464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction Chemotherapy and Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy for Inoperable Pancreas Cancer.
    Chuong MD; Herrera R; Kaiser A; Rubens M; Romaguera T; Alvarez D; Kotecha R; Hall MD; McCulloch J; Ucar A; DeZarraga F; Aparo S; Joseph S; Asbun H; Jimenez R; Narayanan G; Gutierrez AN; Mittauer KE
    Front Oncol; 2022; 12():888462. PubMed ID: 35814383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study.
    Michalet M; Bordeau K; Cantaloube M; Valdenaire S; Debuire P; Simeon S; Portales F; Draghici R; Ychou M; Assenat E; Dupuy M; Gourgou S; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
    Front Oncol; 2022; 12():842402. PubMed ID: 35356227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy With On-Table Adaptive Replanning and Elective Nodal Irradiation for Inoperable Pancreas Cancer.
    Chuong MD; Bryant J; Mittauer KE; Hall M; Kotecha R; Alvarez D; Romaguera T; Rubens M; Adamson S; Godley A; Mishra V; Luciani G; Gutierrez AN
    Pract Radiat Oncol; 2021; 11(2):134-147. PubMed ID: 32947042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic Magnetic Resonance-Guided Daily Adaptive SABR (SMART) for Localised Non-Metastatic Pancreatic Cancer: First Reported Clinical Outcomes From the UK.
    Nugent K; Mukherjee S; Teoh S; George B; Martin A; Gaya A; Aznar-Garcia L; Chu K; Robinson M; Maughan T; Good J
    Clin Oncol (R Coll Radiol); 2024 Sep; 36(9):576-584. PubMed ID: 38902119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma.
    Webking S; Sandoval ML; Chuong MD; Ucar A; Aparo S; De Zarraga F; Sahin I; Biachi T; Kim DW; Hoffe SE; Frakes JM; Palm RF
    Cancer Control; 2023; 30():10732748231219069. PubMed ID: 38038261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
    Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report.
    Doty DG; Chuong MD; Gomez AG; Bryant J; Contreras J; Romaguera T; Alvarez D; Kotecha R; Mehta MP; Gutierrez AN; Mittauer KE
    Med Dosim; 2021 Winter; 46(4):384-388. PubMed ID: 34120803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.
    Hill C; Sehgal S; Fu W; Hu C; Reddy A; Thompson E; Hacker-Prietz A; Le D; De Jesus-Acosta A; Lee V; Zheng L; Laheru DA; Burns W; Weiss M; Wolfgang C; He J; Herman JM; Meyer J; Narang A
    Cancer Med; 2022 Apr; 11(7):1659-1668. PubMed ID: 35142085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer.
    Henke LE; Stanley JA; Robinson C; Srivastava A; Contreras JA; Curcuru A; Green OL; Massad LS; Kuroki L; Fuh K; Hagemann A; Mutch D; McCourt C; Thaker P; Powell M; Markovina S; Grigsby PW; Schwarz JK; Chundury A
    Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):379-389. PubMed ID: 34474109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - A phase II study.
    Weisz Ejlsmark M; Bahij R; Schytte T; Rønn Hansen C; Bertelsen A; Mahmood F; Bau Mortensen M; Detlefsen S; Weber B; Bernchou U; Pfeiffer P
    Radiother Oncol; 2024 Aug; 197():110347. PubMed ID: 38815694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART).
    Bryant JM; Palm RF; Liveringhouse C; Boyer E; Hodul P; Malafa M; Denbo J; Kim D; Carballido E; Fleming JB; Hoffe S; Frakes J
    Adv Radiat Oncol; 2022; 7(6):101045. PubMed ID: 36420193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity.
    Hill CS; Rosati LM; Hu C; Fu W; Sehgal S; Hacker-Prietz A; Wolfgang CL; Weiss MJ; Burkhart RA; Hruban RH; De Jesus-Acosta A; Le DT; Zheng L; Laheru DA; He J; Narang AK; Herman JM
    Ann Surg Oncol; 2022 Apr; 29(4):2456-2468. PubMed ID: 35129721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.
    Paiella S; Malleo G; Simoni N; Micera R; Guariglia S; Cavedon C; Marchegiani G; Esposito A; Landoni L; Casetti L; Tuveri M; Milella M; Secchettin E; Manzini G; Bovo C; De Pastena M; Fontana M; Salvia R; Mazzarotto R; Bassi C
    BMC Cancer; 2021 Feb; 21(1):165. PubMed ID: 33593311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.
    Moningi S; Dholakia AS; Raman SP; Blackford A; Cameron JL; Le DT; De Jesus-Acosta AM; Hacker-Prietz A; Rosati LM; Assadi RK; Dipasquale S; Pawlik TM; Zheng L; Weiss MJ; Laheru DA; Wolfgang CL; Herman JM
    Ann Surg Oncol; 2015 Jul; 22(7):2352-8. PubMed ID: 25564157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.